LGR5, HES1 and ATOH1 in Young Rectal Cancer Patients in Egyptian.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Asian Pacific Organization for Cancer Prevention Country of Publication: Thailand NLM ID: 101130625 Publication Model: Electronic Cited Medium: Internet ISSN: 2476-762X (Electronic) Linking ISSN: 15137368 NLM ISO Abbreviation: Asian Pac J Cancer Prev Subsets: MEDLINE
    • Publication Information:
      Original Publication: Bangkok : Asian Pacific Organization for Cancer Prevention,
    • Subject Terms:
      Gene Expression*; Basic Helix-Loop-Helix Transcription Factors/*genetics ; Receptors, G-Protein-Coupled/*genetics ; Rectal Neoplasms/*genetics ; Transcription Factor HES-1/*genetics; Adult ; Egypt ; Female ; Humans ; Male ; Neoadjuvant Therapy ; Prognosis ; Rectal Neoplasms/drug therapy ; Young Adult
    • Abstract:
      Objective: The study aimed to delineate the gene expression profile of LGR5, HES1 and ATOH1 in young Egyptian rectal cancer (RC) patients and investigate the correlation between expression profiles and clinical outcome.
      Methods: The study was conducted on 30 young Egyptian RC patients. Expression study of LGR5, HES1 and ATOH1 were performed by quantitative PCR (QPCR) based on comparative Cq method after normalization to adjacent non tumor tissues and ACTB as a reference gene. Patients were followed up for assessment of response to neoadjuvant chemoradiotherapy (CRT) based on revised RECIST1.1.
      Result: The study detected overexpression of LGR5 and HES1 and down-regulation of ATOH1 in human RC tissues compared to non- tumor tissues. High expression of LGR5 was correlated with more depth of tumor invasion, lymph node (LN) metastasis, advanced cTNM stage and mesorectal fascia (MRF) involvement. More prominently, high LGR5 expression level was associated with poor response to CRT. LGR5 was suggested as unfavorable prognostic biomarker for RC. Conversely, HES1 and ATOH1 expression did not show significant association with most of the studied clinical criteria nor response to CRT. Still, HES1 and ATOH1 were significantly and inversely associated with presence of mucinous component.
      Conclusion: High LGR5 expression is indicative of poor prognosis among young Egyptian RC patients and is proposed as a predictive marker of resistance to neoadjuvant CRT. However, HES1 and ATOH1 expressions were not prognostic nor predictive of response to CRT. Overall, LGR5, HES1 and ATOH1 gene expression patterns among young onset RC patients, are in line with patterns encountered in older age groups.
    • References:
      Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
      Mol Endocrinol. 1998 Dec;12(12):1830-45. (PMID: 9849958)
      Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):267-73. (PMID: 25193236)
      Gut. 2010 Dec;59(12):1680-6. (PMID: 20926645)
      Gastroenterology. 2010 Sep;139(3):918-28, 928.e1-6. (PMID: 20621629)
      J Pathol. 2009 Dec;219(4):427-34. (PMID: 19621338)
      Oncotarget. 2015 May 20;6(14):12763-73. (PMID: 25906747)
      Ann N Y Acad Sci. 2005 Nov;1059:174-83. (PMID: 16382053)
      Dis Colon Rectum. 2014 Aug;57(8):933-40. (PMID: 25003288)
      Gut. 2013 Jul;62(7):1012-23. (PMID: 22637696)
      Anticancer Drugs. 2015 Oct;26(9):942-7. (PMID: 26196680)
      J Cancer Epidemiol. 2014;2014:437971. (PMID: 25328522)
      Cancer Sci. 2015 Aug;106(8):1000-7. (PMID: 26017781)
      Br J Cancer. 2001 Sep 28;85(7):1037-46. (PMID: 11592777)
      Nat Commun. 2014;5:3149. (PMID: 24476626)
      World J Surg Oncol. 2012 Nov 15;10:244. (PMID: 23153436)
      Oncogene. 2008 Feb 28;27(10):1489-500. (PMID: 17873912)
      Stem Cells. 2012 Dec;30(12):2631-44. (PMID: 23081779)
      Sci Rep. 2016 May 16;6:26069. (PMID: 27181744)
      Oncol Rep. 2010 Aug;24(2):345-50. (PMID: 20596619)
      Br J Cancer. 2010 Jan 19;102(2):351-60. (PMID: 20010940)
      Stem Cells. 2012 Mar;30(3):363-71. (PMID: 22232074)
      Endocrinology. 2009 Nov;150(11):5065-73. (PMID: 19797400)
      CMAJ. 2013 Aug 6;185(11):E537-44. (PMID: 23798453)
      Am J Pathol. 2018 Oct;188(10):2236-2250. (PMID: 30036518)
      PLoS Biol. 2009 Feb 24;7(2):e39. (PMID: 19243219)
      Cell Stem Cell. 2011 Nov 4;9(5):476-85. (PMID: 22056143)
      Sci Rep. 2014 Feb 04;4:3963. (PMID: 24492635)
      Biochem Biophys Res Commun. 2013 Mar 1;432(1):175-81. (PMID: 23333391)
      Lancet. 2009 Mar 7;373(9666):821-8. (PMID: 19269520)
      Am J Pathol. 2008 Sep;173(3):835-43. (PMID: 18688030)
      CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415)
      Br J Cancer. 2013 Aug 20;109(4):1023-30. (PMID: 23900217)
      Int J Cancer. 1997 Mar 28;71(1):26-30. (PMID: 9096661)
      Carcinogenesis. 2014 Apr;35(4):849-58. (PMID: 24282287)
      Acta Pharmacol Sin. 2013 Jun;34(6):732-40. (PMID: 23685952)
      Tumour Biol. 2012 Jun;33(3):817-24. (PMID: 22219033)
      Pharmacogenomics J. 2015 Oct;15(5):391-6. (PMID: 25665511)
      Nat Rev Cancer. 2008 Oct;8(10):755-68. (PMID: 18784658)
      Int J Oncol. 2012 Nov;41(5):1643-52. (PMID: 22923071)
      World J Gastroenterol. 2009 May 14;15(18):2258-64. (PMID: 19437567)
      Cancer Causes Control. 1999 Oct;10(5):349-54. (PMID: 10530604)
      J Clin Pathol. 2009 Dec;62(12):1117-22. (PMID: 19946098)
      Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):50-63. (PMID: 30419314)
      EMBO J. 2009 Jul 8;28(13):1843-54. (PMID: 19521338)
      Int J Colorectal Dis. 2013 Nov;28(11):1535-46. (PMID: 23784051)
      Clin Exp Metastasis. 2015 Feb;32(2):169-79. (PMID: 25636905)
      Oncol Rep. 2009 Oct;22(4):709-17. (PMID: 19724847)
      Exp Cell Res. 2005 Oct 15;310(1):218-28. (PMID: 16120441)
      PLoS One. 2014 Sep 05;9(9):e107013. (PMID: 25192390)
      BMC Cancer. 2015 Dec 16;15:948. (PMID: 26674601)
      Breast Cancer Res Treat. 2008 Oct;111(3):439-48. (PMID: 17990101)
      Oncotarget. 2016 Dec 6;7(49):81144-81155. (PMID: 27835894)
      Am J Surg. 1993 Sep;166(3):257-61. (PMID: 8396358)
      Sci Rep. 2015 Mar 02;5:8654. (PMID: 25728748)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Biomed Pharmacother. 2014 Jun;68(5):507-13. (PMID: 24751002)
      Nature. 2005 Jun 16;435(7044):964-8. (PMID: 15959516)
      Clin Cancer Res. 2006 Sep 15;12(18):5403-10. (PMID: 17000673)
      Dev Biol. 2009 Jul 1;331(1):58-67. (PMID: 19394326)
      Int J Oncol. 2005 Mar;26(3):745-50. (PMID: 15703832)
      Stem Cells. 2012 Nov;30(11):2378-86. (PMID: 22969042)
      Cancer Sci. 2010 Jul;101(7):1731-7. (PMID: 20384634)
      Int J Clin Exp Pathol. 2011 Apr;4(4):327-35. (PMID: 21577318)
      Nat Med. 2012 Mar 11;18(4):618-23. (PMID: 22406745)
      Hum Pathol. 2016 Nov;57:91-97. (PMID: 27476040)
      Dig Dis Sci. 2012 Apr;57(4):845-57. (PMID: 22147253)
      Science. 2001 Dec 7;294(5549):2155-8. (PMID: 11739954)
      World J Gastroenterol. 2014 Dec 14;20(46):17288-96. (PMID: 25516639)
      PLoS One. 2011;6(7):e22733. (PMID: 21829496)
      Int J Clin Exp Pathol. 2014 Sep 15;7(10):7123-30. (PMID: 25400808)
      Cancer Res. 2009 Jan 15;69(2):573-82. (PMID: 19147571)
      Carcinogenesis. 2009 Dec;30(12):1979-86. (PMID: 19793799)
      BMC Cancer. 2016 Jan 12;16:12. (PMID: 26758198)
      Am J Transl Res. 2012;4(3):279-90. (PMID: 22937206)
      Nat Rev Mol Cell Biol. 2014 Jan;15(1):19-33. (PMID: 24326621)
    • Contributed Indexing:
      Keywords: Gene expression; Young colon cancer; cance stem cells chemotherapy prognosis
    • Accession Number:
      0 (ATOH1 protein, human)
      0 (Basic Helix-Loop-Helix Transcription Factors)
      0 (LGR5 protein, human)
      0 (Receptors, G-Protein-Coupled)
      0 (Transcription Factor HES-1)
      149348-15-2 (HES1 protein, human)
    • Publication Date:
      Date Created: 20210928 Date Completed: 20211222 Latest Revision: 20220225
    • Publication Date:
      20231215
    • Accession Number:
      PMC8850894
    • Accession Number:
      10.31557/APJCP.2021.22.9.2819
    • Accession Number:
      34582650